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Abstract
Genetic association studies have identified 21 loci associated with atopic dermatitis risk 
predominantly in populations of European ancestry. To identify further susceptibility loci for this 
common complex skin disease, we performed a meta-analysis of >15 million genetic variants in 
21,399 cases and 95,464 controls from populations of European, African, Japanese and Latino 
ancestry, followed by replication in 32,059 cases and 228,628 controls from 18 studies. We 
identified 10 novel risk loci, bringing the total number of known atopic dermatitis risk loci to 31 
(with novel secondary signals at 4 of these). Notably, the new loci include candidate genes with 
roles in regulation of innate host defenses and T-cell function, underscoring the important 
contribution of (auto-)immune mechanisms to atopic dermatitis pathogenesis.
Atopic dermatitis (eczema) is a common inflammatory skin disease affecting 15–30% of 
children and 5-10% of adults1. Its pathogenesis involves skin barrier abnormalities and a T-
cell-driven cutaneous inflammation. Atopic dermatitis has significant genetic contributions, 
with heritability estimates of up to 90%2 in Europeans. The strongest known risk factors are 
null mutations of the filaggrin (FLG) gene, resulting in epidermal barrier deficiency3-5. 
Genome-wide association (GWA) studies have identified 20 additional loci (10 in 
Europeans, 8 in Japanese, 2 in Chinese populations), mostly implicated in immune 
dysregulation6-12. Genetic modeling suggests further loci may be identified with well-
powered GWAS13. We therefore carried out a multi-ethnic meta-analysis of 26 studies 
comprising 21,399 cases and 95,464 controls imputed to the 1000 Genomes Project Phase 1 
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reference panel (Supplementary Note 1 & Supplementary Table 1). 15,539,996 variants with 
≥1% MAF were analyzed.
A fixed effects meta-analysis of the 22 European studies identified 21 genome-wide 
significant (p<5×10−8) loci (Table 1, Fig 1, Supplementary Figs 1-4), and a multi-ethnic 
meta-analysis identified an additional 6 loci with log10 Bayes Factor>6.1, 4 of which 
(10q21.2, 6p21.33, 11p13, 2p13.3) also showed nominal association in the European 
analysis (Table 1). These 27 loci included all 11 loci previously associated with atopic 
dermatitis in Europeans and 5 loci originally reported in Japanese. Three Japanese loci 
(6p21.33, 10q21.2, 2q12.1) were also strongly associated in the European analysis, whereas 
two (3q13.2, 11p15.4) may represent Japanese-specific signals (Supplementary Figs 1&2), 
with the European confidence interval ruling out all but very small effects (OR<1.03, Table 
1). Furthermore, a locus originally reported in a Chinese GWAS (20q13.33) showed 
association in Europeans. We identified 11 novel loci for atopic dermatitis. Four (11q24.3, 
10p15.1, 8q21.13, 2p25.1) were previously associated with self-reported allergy14, and 
another (8q21.13) with asthma15. Two novel variants (5p13.2 and 2p25.1) showed 
statistically significant evidence of heterogeneity between European and non-European 
studies (Cochran’s Q p~0.01, Supplementary Table 2). Both showed little evidence for 
association in non-Europeans (particularly Japanese, Supplementary Fig.2). The CIs also 
overlapped for all variants when comparing pediatric (defined as onset by age 6) with any-
age onset studies (Supplementary Fig.3). Within Europeans there was some evidence of 
heterogeneity in effect sizes between studies amongst known variants (e.g. 11q13.5 
I2=62.9%, p<0.0001; 11p13 I2=55.6%, p=0.0011) but little evidence amogst novel variants 
(I2 range=0-40%, all p>0.02, Supplementary Fig.2). Nevertheless, studies with phenotype 
definition based on a dermatological exam tended to report larger effect sizes than studies 
using self-report (Supplementary Fig.4), which is to be expected, assuming a moderate 
degree of phenotypic misclassification in the latter. The inclusion of studies utilizing self-
report is therefore likely to bias estimates of the effect size towards the null, and this should 
be borne in mind when interpreting the odds ratios from our study. Given the primary aim of 
GWA studies is the detection of novel loci, the increase in sample size achieved by 
including these studies is so large that any potential detrimental effect on statistical power is 
more than outweighed and the expected direction of bias means there is unlikely to be an 
issue of spurious findings (corroborated by Supplementary Fig.4).”
Seven of the 21 established asthma loci15-20, 7 of the 10 allergic sensitization loci21, and 6 
of 14 self-reported allergy loci14 showed association with atopic dermatitis (p<0.05), all 
with consistent directions of effect, supporting common atopic mechanisms in atopic 
dermatitis and allergy (Supplementary Table 3). However, several studies used here 
contribute to multiple GWASs, which may bias this overlap. Nevertheless, a substantial 
proportion of the loci associated with other atopic conditions appear not to be strongly 
associated with atopic dermatitis.
Twenty-one of the 27 atopic dermatitis-associated loci have previously been implicated in 
other immune-mediated traits (Supplementary Table 4), most notably inflammatory bowel 
disease (IBD) and psoriasis. We therefore compared significant results from GWAS of 
IBD22, psoriasis23, ankylosing spondylitis24, multiple sclerosis25, rheumatoid arthritis26 and 
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type 1 diabetes27with results from our present study of atopic dermatitis. Of 163 established 
IBD risk variants, 39 reached p<0.05 for atopic dermatitis (Supplementary Table 5, 8.1 
expected, p=2.4×10−16), 35 with the same direction of effect (sign test p<0.0001), consistent 
with the observational association between the two diseases28-30. Of the 36 known psoriasis 
variants, 15 reached p<0.05 for atopic dermatitis (Supplementary Table 6, 1.8 expected, 
p=6×10−11), 10 with the same direction of effect (sign test p=0.30). However, these 
conditions rarely clinically co-occur31 and the most strongly associated genetic variants 
show opposite directions of effect32. Therefore our results, suggesting a more complex 
genetic relationship, might warrant further investigation. SNPs robustly associated with 
other auto-immune diseases were also more likely to be nominally associated with atopic 
dermatitis than expected by chance, but there was little evidence of any consistency in 
direction of effect (Supplementary Tables 7–10). These findings did not appear to be 
affected by contamination by common controls across studies. Analyses performed 
excluding common cohorts, yielded similar results (data not shown).
Conditional analysis showed evidence for secondary independent signals at 4 known atopic 
dermatitis loci (2q12.1, 4q27, 11p13, 5q31.1, Supplementary Table 11), one of which 
(5q31.1) has been previously reported9. In the epidermal differentiation complex (1q21.2–3, 
where FLG is located) the signals near MRPS21 (rs7512552) and IL6R (rs12730935 or the 
known functional mutation rs2228145) were independent from FLG, whereas the top signal 
near LCE3E (rs61813875) appears to be partially tagging the R501X FLG mutation 
(r2=0.49) and showed no significant residual association (P>0.05) after conditioning on the 4 
most prevalent FLG mutations (Supplementary Tables 12&13).
To identify additional variants of biological relevance not reaching genome-wide 
significance, we applied gene-set enrichment analysis using Meta-Analysis Gene-set 
Enrichment of variaNT Associations (MAGENTA)33 (Supplementary Table 14). A 
significant enrichment of 22 partially overlapping gene-sets (FDR<=0.01) related to innate 
immune signaling and T-cell polarization was observed (Supplementary Fig.5).
For replication, we selected the lead SNPs from the 11 novel loci, 9 candidate SNPs from 
the MAGENTA analysis (with p<10−5 mapping to gene-sets with FDR<0.05), and 3 SNPs 
representing potentially novel secondary signals. These were investigated in 18 studies 
(32,059 cases and 228,628 controls, Supplementary Table 1). Amongst the European 
studies, 11 of the 20 novel loci reached a Bonferroni-corrected threshold (α=0.0025) with 1-
sided tests in a fixed effects analysis (Table 2). However, one of these showed evidence of 
heterogeneity (10p15.1, p=0.041) and was not significant in a random effects analysis 
(p=0.019, Supplementary Table 15). Two of the gene-set selected SNPs reached genome-
wide significance in the combined analysis (2q37.1, 12q15). A random effects analysis of all 
replication cohorts (European and other ethnicities) show broadly consistent results (though 
only 6 reach genome-wide significance), with no clear population-specific effects 
(Supplementary Table 16 & Fig.6).
All 3 secondary signals showed significant association in the replication-phase conditional 
analysis (Supplementary Table 11).
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As a preliminary step towards understanding the functional underpinnings of the atopic 
dermatitis genetic associations, we established a ‘credible set’ of SNPs (all with strong 
association) for each locus as described in the online methods34. We reviewed these SNPs’ 
functional annotations in ENCODE Consortium and Roadmap Epigenomics Consortium 
data, evaluated expression quantitative trait locus (eQTL) effects in MuTHER35, reviewed 
evidence of differential expression, and surveyed relevant mouse mutants (see 
Supplementary Note 2 and Tables 17–21). Regions of DNase hypersensitivity from the 
ENCODE and Roadmap data36,37 were strongly enriched for atopic dermatitis association 
compared to the rest of the genome (Supplementary Fig.7 & Table 22), particularly in 
immune cells (Th0, Th1, Th17 p<0.0001), this enrichment was observed well below the 
genome-wide significance threshold, indicating the presence of additional undetected risk 
variants. We observed multiple cis-eQTLs (Bonferroni-corrected p<7×10−4) in 
lymphoblastoid cell lines (LCLs) or skin (Supplementary Tables 17&19). The most 
significant were two variants from the credible set at 2p13.3, which were strong eQTLs for 
CD207/langerin in skin (rs4852714 p=1.23×10−10, rs6723629 p=1.67×10−10, LD with lead 
SNP r2=0.56, D’=0.96, and r2=0.53, D’=0.93, respectively, 99% posterior probability that 
atopic dermatitis and eQTL signals colocalize). rs4852714 is also in an open-chromatin 
region with histone marks indicative of promoter/enhancer activity in LCLs (Supplementary 
Tables 18,19 & Fig.8). CD207 encodes an intracellular pattern recognition receptor 
expressed in subpopulations of dendritic cells, in particular epidermal Langerhans cells 
(LCs) which play a vital role in the induction of tolerance and direction of adaptive immune 
responses38. CD207 binds to carbohydrates present e.g. on microorganisms and exerts anti-
viral/anti-fungal defense mechanisms39. Of note, atopic dermatitis is characterized by an 
increased susceptibility towards skin infection with pathogens such as Staphylococcus 
aureus, herpes simplex virus, and Malassezia species40, and differences in langerin function 
might contribute to this dysregulated cutaneous immunity.
There is longstanding evidence that skin barrier defects and inappropriate immune responses 
to environmental antigens1 contributes to atopic dermatitis. However, evidence for 
autoimmune mechanisms, in particular in the context of progression to the chronic phase, 
has only recently emerged41. Interestingly, the majority of our novel susceptibility loci 
harbor candidate genes with functional annotations related to autoimmunity. At 14q13.2, the 
lead SNP (rs2038255) is intronic to PPP2R3C (a protein phosphatase component regulating 
B-cell maturation and survival), the dysregulation of which has been associated with murine 
autoimmunity42 and the signal colocalizes with a strong KIAA0391 eQTL signal 
(Supplementary Table 19). The lead 5p13.2 variant (rs10214237) is located 4kb downstream 
of the gene encoding the alpha-chain of the IL7 receptor (IL7R), which is a key mediator in 
T-cell-driven autoimmunity and inflammation43. Of interest, the credible set contains an 
IL7R missense variant (rs6897932, p=1.6×10−7, r2=0.94 with lead SNP), which displays the 
same effect direction with multiple sclerosis44,45. The risk allele leads to an enhanced 
bioavailability of IL746, which in mice causes severe dermatitis with intense pruritus and 
high IgE levels, i.e. atopic dermatitis-like features47. Likewise, as part of the autosomal-
dominant hyper-IgE syndrome, rare dominant negative mutations in the gene encoding 
STAT3 (in which our lead 17q21.2 variant is intronic) cause severe dermatitis and high 
serum IgE levels, as well as recurrent S.aureus skin infections, which may be driven by 
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impaired Th17 cell differentiation and effector function48,49. STAT3 might thus represent an 
example for risk gene/pathway shared between a complex trait and a related Mendelian 
condition50,51, harboring highly penetrant severe effect rare mutations and common milder 
effect variants. At 8q21.13, the closest candidate gene is ZBTB10 encoding a zinc finger 
protein, which is a putative repressor of the Sp1, Sp3 and Sp4 transcription factors52. 
Variants in moderate LD (r2>0.7) with the lead variant for atopic dermatitis were previously 
associated with self-reported allergy14 and a combined asthma and hay fever phenotype53. 
However, although not excluding ZBTB10 as the causal gene, the credible SNP set 
comprises a 47kb interval on the other side of a recombination peak (60cM/Mb). The variant 
most likely to be regulatory amongst this set, deletion rs5892724 (r2=0.82 with lead SNP), is 
located in open chromatin in several cell types including CD4+ helper T-cells, and affects a 
STAT3 binding site49,54. At 11q24.3 the most plausible candidate gene is ETS1, which 
encodes a transcription factor with a range of immune functions including Th17 and B-cell 
differentiation and function; ETS1-deficient mice display autoimmune features55. ETS1 
appears to be additionally involved in keratinocyte differentiation and formation of the 
cornified envelope56. Additional variants identified through the gene-set approach implicate 
genes with cytokine signaling functions (INPP5D, TRAF3, SOCS3 and a cytokine cluster on 
12q15).
In conclusion, we have identified 10 new loci robustly associated with atopic dermatitis in 
Europeans (6 of which also reach genome-wide significance in random effects analysis 
across studies of all ethnicities), bringing the total number of susceptibility loci to 31 (24 in 
Europeans), with evidence of secondary signals at 4 of these. Altogether, in the subset of 
European studies with clinically defined cases, previously established and newly identified 
variants explain approximately 12.3% and 2.6% of the variance in liability, respectively 
(Supplementary Table 23). All novel susceptibility loci are related to (auto-)immune 
regulation, in particular innate signaling and T-cell activation and specification, and there 
appears to be a substantial genetic overlap with other inflammatory and autoimmune 
diseases. Whilst not detracting from the importance of maintaining the skin barrier in the 
prevention and treatment of atopic dermatitis, our findings lend support to new therapeutic 
approaches targeted at immune modulation57.
ONLINE METHODS
GWAS meta-analysis
We carried out genome-wide association (GWA) analysis for atopic dermatitis case/control 
status in 26 individual studies (Supplementary Table 1), comprising a total of 21,399 cases 
and 95,464 controls. The majority of these studies included individuals of only European 
ancestry (22 studies, 18,900 cases, 84,166 controls). We also included one study of Japanese 
individuals (RIKEN, 1,472 cases. 7,966 controls), one study of African American 
individuals (SAPPHIRE, 422 cases and 844 controls), one study of Latin American 
individuals (GALA II, 300 cases, 1,592 controls) and one study with individuals of mixed 
non-European ancestry (Generation R, 305 cases, 896 controls).
Each cohort separately imputed their genetic data to 1000 Genomes Project Phase 1 (the 
majority to the March 2012 release, Supplementary Table 1) and carried out GWA analysis 
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across all imputed variants. Before meta-analysis we restricted each study to only those 
variants with minor allele frequency (MAF)>1% and moderate imputation quality score 
(Rsq>0.3 for variants imputed in MACH and proper info>0.4 for IMPUTE). For some 
cohorts additional quality control filters were applied (full methods for each study are 
available in Supplementary Note 1).
Meta-analysis was conducted for Europeans only in GWAMA (using fixed effects) and for 
all ethnicities combined in MANTRA60. Rather than imposing a fixed or random effects 
model, MANTRA accounts for the heterogeneity of effects between ethnicities by allowing 
the studies to cluster according to allele frequency profile (and hence population genetic 
similarity). To prevent very small European studies (with less precise estimates of the allele 
frequencies) from having undue weight in our analysis we fixed the Europeans to cluster 
together by using the European fixed effects results in the MANTRA analysis. Variants with 
p<5×10−8 in the European analysis were considered to be associated, as were any additional 
variants with (log10) Bayes Factor (BF)>6.1 (equivalent to p<5×10−8)61 in the MANTRA 
analysis. Each locus is represented in the results table by the variant with the strongest 
evidence for association. Heterogeneity was assessed using the I2 statistic and Cochrane’s Q 
test. Meta-analysis results were also stratified according to ethnicity, method of case 
diagnosis and age of onset to explore sources of heterogeneity.
For the Epidermal-differentiation complex region (where the FLG gene is located and which 
has previously shown complex association results), we repeated the association tests (across 
the region between 150.2–154.5Mb on chromosome 1) conditioning on the four most 
common FLG variants (R501X, 2282del4, R2447X, S3247X) in the individual studies 
where these were available (10 studies, 20,384 individuals, Supplementary Table 12). These 
were meta-analyzed to identify whether there were any remaining independent association 
signals in this region.
Identification of independent secondary signals at associated loci
To identify secondary independent signals at each of the other associated loci, we carried out 
conditional analysis of the European meta-analysis results using GCTA62, with the 
ALSPAC 1000 Genomes imputation (restricted to variants with MAF>1% and imputation 
quality proper info score>0.8) serving as the reference. The regions tested were +/−250kb 
surrounding the top hit at each locus. Locus specific significance thresholds were estimated 
by first calculating the effective number of tests in each 500kb region using Nyholt’s 
procedure63 and the 1000 Genomes reference data (European). For each locus we estimated 
the new threshold for locus-wide error rate of 5% by dividing alpha (0.05) by the 
corresponding number of effective tests in that region (α-values are shown in 
Supplementary Table 11). For 4q27 we defined the region as +/−500kb as a known hit was 
just less than 500kb from the top SNP in our analysis. We conditioned each region on the 
top hit from our meta-analysis. Any variant that surpassed the locus-specific threshold was 
considered an independent secondary signal.
Paternoster et al. Page 6
Nat Genet. Author manuscript; available in PMC 2016 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
MAGENTA gene-set enrichment analysis
We tested our meta-analysis results for enriched gene-sets using MAGENTA33. This 
method assigns SNPs to genes based on genomic distance (SNPs are assigned if within 
110kb upstream or 40kb downstream of each gene), and generates gene-based summary p-
values. Subsequently, genes are assigned to gene-sets (using curated repositories including 
GO-data, Biocarta, PANTHER, KEGG, etc.) and each gene-set is assigned a p-value by 
comparing gene summary p-values to a null model where SNPs are drawn randomly 10,000 
times (normalizing for the number of SNPs genotyped in each gene) and controlling for 
false discovery rate (FDR) at α=0.05. ~10,000 gene-sets were tested. As MAGENTA 
requires a p-value as input and to take account of the differing effects between populations, 
we re-analyzed our meta-analysis of all studies using a random effects model, to serve as 
input to the MAGENTA analysis. All genes in the HLA region (chr6:29710331–33150000) 
were removed from the analysis. In order to identify additional variants of interest to take 
forward to replication we examined any pathway with FDR<0.05. From these gene-sets we 
took forward to replication any additional loci with a genetic variant p<10−5.
Cross-phenotype comparisons
The NHGRI GWAS catalog64 was mined for traits with reported associations at each of our 
genome-wide significant loci. To further investigate the genetic overlap between atopic 
dermatitis and auto-immune diseases, we took the genome-wide significant loci from recent 
GWAS of IBD22 and psoriasis23 ankylosing spondylitis24, multiple sclerosis25, rheumatoid 
arthritis26 and type 1 diabetes27 and extracted the atopic dermatitis results for these variants 
from our European discovery GWAS, noting whether the variant was associated (p<0.05) 
with atopic dermatitis (testing enrichment of overlap using the 2-sided binomial exact test) 
and carried the same or opposite direction of effect between the two traits (tested using the 
sign test).
Replication
The top SNP from the 11 novel associated regions (log10BF>6.1 or p<5×10−8) were taken 
forward to replication, along with 9 suggestively associated SNPs (p<10−5) that were in 
genes highlighted in the MAGENTA analysis as good candidates. In addition, we included 
any variants with evidence for being secondary independent signals at associated loci. 
Replication consisted of 18 studies (32,059 cases and 228,628 controls) with genome-wide 
imputed data available or custom genotyping (Supplementary Table 1). Studies of European 
ethnicity were combined in fixed effects meta-analyses in GWAMA. We also carried out 
random effects meta-analysis for the European studies to assess association for variants 
which showed evidence of heterogeneity (p<0.05). Significant association in the replication 
phase was determined by 1-sided p-values meeting a Bonferroni-corrected threshold 
(α=0.05/20=0.0025). Random effects meta-analyses of replication studies of all ethnicities 
were also carried out and forest plots examined for evidence of population-specific effects. 
For the replication of the three secondary signals, the secondary SNPs were tested for 
association after conditioning on the top SNP in each of the European cohorts. These results 
were then combined in fixed effects meta-analyses.
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Credible sets
In order to assemble a sensible list of variants at each locus for functional look-ups, we 
constructed credible sets34 that represent those SNPs most likely to be causal based on 
statistical evidence from the MANTRA analysis (or from the European analysis for the three 
variants that appeared to be European-specific). The European-only GWAS was repeated in 
MANTRA to generate BFs required for the credible set analysis. Bayes factors were used to 
calculate posterior probabilities for all SNPs in each region (+/−1Mb), the minimum set of 
SNPs that had a cumulative posterior probability of at least 95% made up each credible set. 
These sets can be interpreted similar to confidence intervals, in that assuming the association 
signal at a locus can be attributed to a single causal variant (and that the true causal variant 
is included in the analysis and has been well-imputed), the 95% credible set contains that 
causal variant with 95% probability. Given that a 1000 Genomes imputation analysis may 
not include the true causal variant or that the associations may be driven by more than one 
causal variant, we do not expect these credible sets to necessarily contain the causal variants 
at the suggested 95% probability. Nevertheless, they demonstrate in addition to the ‘top 
SNP’, which neighbouring variants also show strong association with atopic dermatitis and 
we find them useful in assessing the size of the regions of interest and for defining a set of 
variants to follow-up. As the posterior probabilities for the MAGENTA identified credible 
sets are extremely large (due to the weaker signals at these loci), we instead carried out 
functional look-ups for all variants with r2>=0.8 of the top hit for these loci.
Functional look-ups
For variants identified as part of a credible set, we carried out look-ups in the following 
functional data resources; (i) regulomeDB and Haploreg were mined for evidence of coding 
or regulatory function (these resources collate annotations [e.g., coding variation, regulatory 
chromatin marks, DNase I hypersensitivity, protein binding and motif alteration] from the 
ENCODE Consortium, the NIH Roadmap Epigenomics Mapping Consortium, and the 
literature over a wide range of tissues); (ii) cis-eQTL for skin or LCLs were identified from 
the MuTHER consortium35 (with variants considered eQTLs if association with any 
transcript within 1Mb was p<7×10−4, corresponding to a bonferroni correction for 36 loci 
and 2 tissues); (iii) differential expression reported for implicated genes between uninvolved 
skin from cases and skin from controls65 and between lesional and non-lesional skin in 
atopic dermatitis patients in a study deposited in the Gene Expression Omnibus 
(Accession=GDS4444)66; and (iv) mouse mutants of implicated genes were examined in the 
MGI database.
Colocalization of atopic dermatitis GWAS signals and eQTLs in the MuTHER data was 
investigated using the R package coloc67. All SNPs within 100kb of the lead atopic 
dermatitis SNP were included in the analysis and we report the posterior probabilities that 
the two signals colocalize in Supplementary Table 19.
To identify and visualize cell types implicated in atopic dermatitis pathogenesis, the 
tendency of disease associated loci to fall in cell-type specific regulatory DNase 
Hypersensitive Sites (DHS) (a proxy for accessible and/or regulatory DNA) was calculated 
for the full range of p-values, essentially as done by Maurano et al.68. This enrichment was 
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computed for 168 cell types and cell lines in the ENCODE Roadmap repository36. 
Duplicates and directly redundant cell types were removed before analysis. One-sided p-
values for enrichment were calculated from an empirical null distribution of loci overlap for 
DHS-regions, generated by 10,000 random permutations of overlapping an identical number 
of random loci as found at p<=1×10−10 with all DHS-regions for all cell- and tissue types.
Variance in liability explained
We estimated the proportion of variance in atopic dermatitis liability explained by the 
established and novel variants in a subset of studies that had clinically diagnosed cases 
(GENEVA/KORAF4/POPGEN, NCRC-ADC, GENUFADex-SHIP1, GENUFAD-SHIP2, 
GENEVA(replication), CECCS) using the method of So et al. (2011)69.
Data access
Genome-wide results are available on request to the corresponding author, on condition of 
signing any Data Transfer Agreements required according the IRB-approved protocols of 
contributing studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Atopic dermatitis GWAS meta-analysis results
(A) Manhattan plot of European fixed effects meta-analysis. (B) Manhattan plot of the 
multi-ethnic MANTRA meta-analysis of all studies. Arrows mark variants not associated in 
the European-only analysis. (C) QQ plot of the European analysis - lambda=1.054.
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